Breakthrough in Genomic Diagnostics: Dubai Health's Long-Read Sequencing Study

The recent publication in Nature Communications by researchers from Dubai Health's Genomic Medicine Center marks a pivotal advancement in diagnosing rare diseases. Titled "Long Read Sequencing Enhances Pathogenic and Novel Variation Discovery in Patients with Rare Diseases," the study demonstrates how long-read whole-genome sequencing (LRS WGS) can uncover genetic variants missed by conventional short-read sequencing (SRS), achieving a 10% diagnostic yield in previously undiagnosed cases. This innovation positions Dubai Health at the forefront of genomic medicine in the United Arab Emirates (UAE), integrating cutting-edge technology with clinical practice to shorten diagnostic odysseys that often span years for patients with rare conditions.

Rare diseases, defined as conditions affecting fewer than 1 in 2,000 people, number over 7,000 globally, with genetic causes in most cases. In the UAE, high consanguinity rates amplify the prevalence of such disorders, making precise diagnostics crucial. The study's lead contributors, including Emirati PhD student Fatma Rabea and senior author Ahmad Abou Tayoun, developed a streamlined filtration strategy that detects small and large structural variants (SVs), copy number variants (CNVs), single nucleotide variants (SNVs), and abnormal methylation episignatures—all from a single LRS dataset.

Understanding Short-Read vs. Long-Read Sequencing Technologies

Short-read sequencing (SRS), the current standard like Illumina platforms, excels at SNVs and small insertions/deletions (INDELs) but struggles with repetitive regions, complex SVs, and epigenetic marks. Long-read sequencing (LRS), using Oxford Nanopore's PromethION, generates reads averaging 11.7 kb (N50), enabling phasing across genes, repeat resolution, and direct methylation detection without bisulfite conversion.

In the Dubai Health study, LRS targeted ≥30x coverage on whole genomes from high-molecular-weight DNA. Bioinformatics pipelines like Epi2Me, CuteSV, and custom "funnel-down" filters reduced ~35,000 SVs per genome to inspectable candidates in disease genes (OMIM/GenCC), prioritizing high allele fractions and unique cohort variants. This approach validated 100% sensitivity for known pathogenic changes in controls while identifying novel ones in unsolved cases.

• LRS advantages: SV phasing (e.g., compound heterozygotes), episignature profiling for 36 Mendelian neurodevelopmental disorders (MNDD), novel biomarkers like SMA methylation tag.
• SRS limitations: Misses 50%+ of cases due to inaccessible regions; no native phasing/methylation.

The Study Cohort and Methodology in Detail

The research cohort comprised 51 pediatric and adult patients (90% Arab descent, 44% female) with negative prior SRS exome sequencing (WES) or chromosomal microarray analysis (CMA). Symptoms predominantly neurological (45%). A positive control set (N=76) confirmed workflow reliability: all 17 known genomic variants and 57 methylation profiles detected flawlessly.

Workflow steps:

• DNA extraction (6000 ng HMW gDNA).
• Ligation-based library prep (SQK-LSK114).
• Sequencing (R10.4.1 pores, HAC basecalling).
• Alignment (minimap2 to hg19).
• Variant calling: SNPs/SVs/methyl via Epi2Me; CNVs via ClassifyCNV.
• Filtration: Disease-gene focus, AF≥0.3 (SVs), log2FC≥0.5 (CNVs), manual IGV review.
• Validation: ddPCR, CMA, RNA-seq for expression.

Key Findings: 10% Diagnostic Yield and Specific Cases

Among the 51 unsolved cases, LRS yielded diagnoses in 5 (10%), comparable to reanalysis rates but with novel insights:

• OXN-033: De novo 1.4 Mb 2q11.1-q11.2 deletion (developmental delay).
• OXN-048: Phased compound heterozygous 80 kb SLC38A8 deletion (anterior segment dysgenesis).
• OXN-027: Homozygous 3.6 kb MPLKIP 3'UTR deletion (trichothiodystrophy-like; RNA-seq showed overexpression).
• OXN-062: NSD1 duplication with MNDD episignature (Hunter-McAlpine syndrome).
• OXN-060: Novel SMA methylation tag (biallelic SMN1 loss, 4 SMN2 copies; treatable with nusinersen).

The SMA tag (chr5:70,239,954-70,249,165) distinguishes patients (0-15% methylation), carriers (50-70%), and non-carriers (98-100%), validated via read deconvolution using 16 polymorphic sites.

Novel SMA Methylation Biomarker: A Game-Changer

Spinal muscular atrophy (SMA), caused by SMN1 loss, affects 1:10,000 newborns. Standard diagnostics rely on copy number (MLPA), missing epigenetic clues. The study's SMA tag leverages LRS's native methylation to detect biallelic deletions precisely, even with compensating SMN2 copies. This could expedite therapy for treatable SMA, reducing infant mortality.

Broader implications: Epimarker module profiles 36 MNDD with 100% accuracy, unifying genomic/epigenomic testing.

Dubai Health Genomic Medicine Center: Hub of Innovation

Dubai Health's Genomic Medicine Center (GMC), under Dubai Academic Health Corporation (DAHC), consolidates rare disease testing. Affiliated with MBRU, it offers PhD/Master's in Biomedical Sciences with scholarships, fostering talents like Fatma Rabea. Dr. Rasha Buhumaid, MBRU Dean, emphasized: "This reflects our commitment to scientific research and patient-first care."

The center integrates WGS for newborns and premarital screening, aligning with UAE's Emirati Genome Programme.

Interested in genomics careers? Check UAE academic opportunities or research jobs at leading institutions.

UAE's Broader Genomics Landscape and Rare Disease Initiatives

The UAE leads regionally in genomics: Emirati Genome Programme sequences 100% Emiratis by 2027; gene therapy for autism/rare disorders launched 2026. Dubai Health's LRS adoption supports national strategies for personalized medicine, high consanguinity challenges, and economic diversification via biotech.

• Arab Pangenome Reference (2025, Nature Comm.): HiFi LRS for UAE diversity.
• Al Jalila Children's Hospital: Nanopore for pediatric rare diseases.

Implications for Global Rare Disease Diagnosis

LRS reduces costs long-term by unifying tests, shortening odysseys (avg. 6 years), enabling therapies like SMA nusinersen. Reviews confirm LRS boosts yields 10-20% in unsolved cases, ideal for repeats/SVs/epigenetics. Challenges: Standardization, annotation; Dubai's workflow addresses this.

Future Directions and Challenges in LRS Adoption

Prospects: Integrate LRS into routine UAE diagnostics; expand episignatures; AI for filtration. Challenges: Cost (dropping), compute needs, validation. Dubai Health eyes scalability via MBRU partnerships.

For aspiring researchers, craft a winning academic CV and explore postdoc positions.

Photo by Lyle Hastie on Unsplash

Career Opportunities in UAE Genomics and Higher Education

This study highlights UAE's biotech boom. MBRU offers PhD scholarships; Dubai Health recruits genomicists. UAE university jobs abound in genomics. Rate professors at Rate My Professor for insights. Browse higher ed jobs or university jobs today.